Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 352

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

Antidepressants versus placebo for depression in primary care

Open access
Arroll, Bruce, Elley, C Raina, Fishman, Tana, Goodyear-Smith, Felicity A, Kenealy, Tim, Blashki, Grant, Kerse, Ngaire, MacGillivray, Stephen·2009·Cochrane Database of Systematic Reviews

Abstract

BACKGROUND: Concern has been expressed about the relevance of secondary care studies to primary care patients specifically about the effectiveness of antidepressant medication. There is a need to review the evidence of only those studies that have been conducted comparing antidepressant efficacy with placebo in primary care-based samples. OBJECTIVES: To determine the efficacy and tolerability of antidepressants in patients (under the age of 65 years) with depression in primary care. SEARCH STRATEGY: All searches were conducted in September 2007.The Cochrane Depression, Anxiety and Neurosis Group (CCDAN) Controlled Trials Register was searched, together with a supplementary search of MEDLINE, PsycINFO, EMBASE, LILACS, CINAHL and PSYNDEX. Abstracts of all possible studies for inclusion were assessed independently by two reviewers. Further trials were sought through searching the reference lists of studies initially identified and by scrutinising other relevant review papers. Selected authors and experts were also contacted. SELECTION CRITERIA: Studies were selected if they were randomised controlled trials of tricyclic antidepressants (TCAs) or selective serotonin reuptake inhibitors (SSRIs) versus placebo in adults. Older patients (over 65 years) were excluded. Patients had to be recruited from a primary care setting. For continuous outcomes the Hamilton Depression scale of the Montgomery Asberg Scale was requred. DATA COLLECTION AND ANALYSIS: Data were extracted using data extraction forms by two reviewers independently, with disagreements resolved by discussion. A similar process was used for the validity assessment. Pooling of results was done using Review Manager 5. The primary outcome was depression reduction, based on a dichotomous measure of clinical response, using relative risk (RR), and on a continuous measure of depression symptoms, using the mean difference (MD), with 95% confidence intervals (CI). MAIN RESULTS: There were fourteen studies (16 comparisons) with extractable data included in the review, of which ten studies examined TCAs, two examined SSRIs and two included both classes, all compared with placebo. The number of participants in the intervention groups was 1364 and in the placebo groups 919. Nearly all studies were of short duration, typically 6-8 weeks. Pooled estimates of efficacy data showed an RR of 1.24, 95% CI 1.11-1.38 in favour of TCAs against placebo. For SSRIs this was 1.28, 95% CI 1.15 to 1.43.. The numbers needed to treat (NNT) for TCAs ranged from 7 to 16 {median NNT 9} patient expected event rate ranged from 63% to 26% respectively) and for SSRIs from 7 to 8 {median NNT 7} (patient expected event rate ranged from 48% to 42% respectively) . The numbers needed to harm (NNH for withdrawal due to side effects) ranged from 4 to 30 for TCAs (excluding three studies with no harmful events leading to withdrawal) and 20 to 90 for SSRIs. AUTHORS' CONCLUSIONS: Both TCAs and SSRIs are effective for depression treated in primary care.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd007954

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 65 references

Research works printed but not linked: 16

  1. Blashki, 1971, Controlled trials of amitriptyline in general practice, BMJ, 1, 133, 10.1136/bmj.1.5741.133 · DOI
  2. Lepola U Loft H Reines EH Escitalopram is efficacious and well tolerated for the treatment of depression in primary care Abstract: Annual meeting the American Medical Association. New Orleans 2001 · DOI
  3. Lepola, 2003, Escitalopram (10-20mg/day) is effective and well tolerated in a placebo controlled study in depression in primary care, International Journal of Clinical Psychopharmacology, 18, 211, 10.1097/01.yic.0000074988.54339.7c · DOI · Paper page
  4. Andersen, 1993, Pathological crying and emotional lability - a controlled study of citalopram - a SSRI, Canadian Journal of Neurological Sciences, 20, S115
  5. Bakish, 1992, A double-blind placebo-controlled comparison of moclobemide and amitriptyline in the treatment of depression, Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie, 37, 12
  6. Gomez, 1968, The treatment of anxiety and depression in general practice using an amitriptyline-perphenazine preparation, British Journal of Clinical Practice, 22, 105
  7. Houston, 1983, Amitriptyline for depressed women with young children in general practice, British Journal of Psychiatry, 142, 103, 10.1017/S0007125000114175 · doi:10.1017/s0007125000114175
  8. Jacobs, 1965, Approach to studying drug effects in ambulatory patients, Archives of General Psychiatry, 13, 163, 10.1001/archpsyc.1965.01730020065008 · doi:10.1001/archpsyc.1965.01730020065008
  9. Lehmann, 1976, A double-blind comparative clinical trial with maprotiline (Ludiomil) and imipramine in newly-admitted depressed patients, Current Therapeutic Research, Clinical and Experimental, 19, 463
  10. O'Hara, 1978, Maprotiline and fluphenazine/nortriptyline in depression, Practitioner, 221, 419
  11. Rickels, 1968, Iprindole in neurotic depressed general practice patients: A controlled study, Psychosomatics, 9, 208, 10.1016/S0033-3182(68)71844-2 · doi:10.1016/s0033-3182(68)71844-2
  12. Rickels, 1971, The combination of protriptyline and oxazepam in depressed neurotic general-practice patients, Psychosomatics, 12, 341, 10.1016/S0033-3182(71)71499-6 · doi:10.1016/s0033-3182(71)71499-6
  13. Schiff, 1975, Non-pharmacological factors in drug therapy: The inter-action of doctor, patient and tablet appearance in the treatment of anxiety/depressive syndromes, Journal of International Medical Research, 3, 125, 10.1177/030006057500300211 · doi:10.1177/030006057500300211
  14. Sussex Clinical Trials Group, 1985, Separate and combined anxiolytic and anti-depressant treatment of mixed anxiety/depression. A double-blind, placebo controlled comparison, Acta Psychiatrica Scandinavica, 72, 81, 10.1111/j.1600-0447.1985.tb02575.x · doi:10.1111/j.1600-0447.1985.tb02575.x
  15. Ellis, 2002, Treating depression: the beyond blue guidelines for treating depression in primary care, Medical Journal of Australia, 176, S77
  16. National Coordinating Centre for Health Technology Assessment, 2000, Health technology briefing paper: Drug treatment of mild depression

Cited by

See all 352

Metadata

Authors
Arroll, B., Elley, C. R., Fishman, T., Goodyear-Smith, F. A., Kenealy, T., Blashki, G., Kerse, N., & MacGillivray, S.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2009-07-08
Volume
2014
Issue
4
Pages
CD007954-CD007954
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W2134058147
Cited by
352
References
65
FWCI
16.01
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antidepressants versus placebo for depression in primary care. https://app.cochat.ai/papers/10.1002/14651858.cd007954
The paper
Arroll, B., Elley, C. R., Fishman, T., Goodyear-Smith, F. A., Kenealy, T., Blashki, G., Kerse, N., & MacGillivray, S. (2009). Antidepressants versus placebo for depression in primary care. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd007954

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.